Anne Kallioniemi

Anne Kallioniemi

Auto-generated profile, based on publicly available information

Anne Kallioniemi

BioMediTech and FimLab Laboratories, University of Tampere, Tampere, Finland

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1998 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JKJuha Kononen
Juha Kononen
LBLukas Bubendorf
Lukas Bubendorf
AKAnne Kallionimeni
Anne Kallionimeni
MBMaarit Bärlund
Maarit Bärlund
PSPeter Schraml
Peter Schraml
OKOlli-P. Kallionimeni
Olli-P. Kallionimeni

30 October 1992 in Science
Verified
Journal Article
Closed access
PDF file
AKAnne Kallioniemi
Anne Kallioniemi
OKOlli-P. Kallioniemi
Olli-P. Kallioniemi
DSDamir Sudar
Damir Sudar
DRDenis Rutovitz
Denis Rutovitz
JGJoe W. Gray
Joe W. Gray
DPDan Pinkel
Dan Pinkel
Comparative genomic hybridization produces a map of DNA sequence copy number as a function of chromosomal location throughout the entire genome. Differentially labeled test DNA and normal reference DNA are hybridized simultaneously to normal chromosome spreads. The hybridization is detected with two different fluorochromes. Regions of gain or loss of DNA sequences, such as deletions, duplications, or amplifications, are seen as changes in the ratio of the intensities of the two fluorochromes along the target chromosomes. Analysis of tumor cell lines and primary bladder tumors identified 16 different regions of amplification, many in loci not previously known to be amplified.

7 August 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
AAAntonis C. Antoniou
Antonis C. Antoniou
SCSilvia Casadei
Silvia Casadei
THTuomas Heikkinen
Tuomas Heikkinen
DBDaniel Barrowdale
Daniel Barrowdale
KPKatri Pylkäs
Katri Pylkäs
MTMarc Tischkowitz
Marc Tischkowitz
To the Editor: We read the article by Antoniou et al. (August 7 issue)1 because we like to know the penetrance of breast-cancer genes before we recommend surgery. After reading the article, we are unsure of what to tell patients. The simplest message would be that the risk up to 70 years of age is 35%, but this is based on an analysis of patients who received a diagnosis of breast cancer from 1930 to the present. The relevant risk value is that for a woman without breast cancer who is found to have a PALB2 mutation today. Most patients . . .

1 August 1994 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
OKOlli‐P. Kallioniemi
Olli‐P. Kallioniemi
AKAnne Kallioniemi
Anne Kallioniemi
JPJim Piper
Jim Piper
JIJorma Isola
Jorma Isola
FWFred M. Waldman
Fred M. Waldman
DPDan Pinkel
Dan Pinkel

15 March 1994 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AKA Kallioniemi
A Kallioniemi
OKO P Kallioniemi
O P Kallioniemi
JPJ Piper
J Piper
MTM Tanner
M Tanner
TST Stokke
T Stokke
FWF M Waldman
F M Waldman
Comparative genomic hybridization was applied to 5 breast cancer cell lines and 33 primary tumors to discover and map regions of the genome with increased DNA-sequence copy-number. Two-thirds of primary tumors and almost all cell lines showed increased DNA-sequence copy-number affecting a total of 26 chromosomal subregions. Most of these loci were distinct from those of currently known amplified genes in breast cancer, with sequences originating from 17q22-q24 and 20q13 showing the highest frequency of amplification. The results indicate that these chromosomal regions may contain previously unknown genes whose increased expression contributes to breast cancer progression. Chromosomal regions with increased copy-number often spanned tens of Mb, suggesting involvement of more than one gene in each region.

15 June 1992 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
OKO P Kallioniemi
O P Kallioniemi
AKA Kallioniemi
A Kallioniemi
WKW Kurisu
W Kurisu
ATA Thor
A Thor
LCL C Chen
L C Chen
JGJ W Gray
J W Gray
We illustrate the use of fluorescence in situ hybridization (FISH) for analysis of ERBB2 oncogene copy number, the level of amplification (here defined as the ratio of ERBB2 copy number to copy number of chromosome 17 centromeres), and the distribution of amplified genes in breast cancer cell lines and uncultured primary breast carcinomas. The relative ERBB2 copy number determined by FISH in 10 breast cancer cell lines correlated strongly with Southern blot results (r = 0.98) when probes for an identical reference locus were used in the two methods. Metaphase analysis of cell lines showed that amplified ERBB2 copies always occurred in intrachromosomal clusters but that the number and chromosomal location of these clusters varied among the cell lines. In interphase nuclei of primary tumors showing ERBB2 amplification (10/44), ERBB2 copies were seen as one to four clusters, also suggesting intrachromosomal localization. Regardless of the average level of amplification, all these tumors contained highly amplified cell subpopulations with at least 25, and sometimes more than 100, ERBB2 copies per cell. Tumors that did not show amplification by FISH (34/44) had an average of one to five ERBB2 copies scattered randomly in the nuclei and completely lacked cells with high copy levels. FISH results on primary tumors were concordant with slot blot results on amplification and with immunohistochemical detection of overexpression. Quantitative analysis of ERBB2 amplification by FISH may improve prognostic assessments based on the pattern of amplification and detection of heavily amplified tumor cell subpopulations.